Recommended

AVAILABLE TO WATCH NOW | Discover how to understand pain pathways and accelerate the search for next-generation analgesics
The truth about AI in drug discovery: what the experts really think | REGISTER FOR THE FREE WEBINAR
ACCESS THE FREE RECORDING | Top cancer researchers explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
NEW REPORT | Explore how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
The scientific advances driving cancer drug discovery – find out more
Meet the precision peptide changing how we study pain
news

Artificial intelligence could revolutionise glycomics datasets

Researchers have created a tool that allows glycomics datasets to be analysed using artificial intelligence for early cancer diagnoses.

Female doctor using AI screen

A team at the University of California (UC) San Diego, US, have developed a tool called GlyCompare that enables researchers to analyse glycomics datasets using artificial intelligence (AI), potentially leading to early cancer diagnoses.

GlyCompare takes a systems-level perspective that accounts for shared biosynthetic pathways of glycans within and across samples. According to the team, one of the keys to the GlyCompare approach is that it looks at the biological steps needed to synthesise the subunits that make up glycans, rather than only looking at only the whole glycans themselves, thereby improving the accuracy of statistical analyses of glycomics data.

To introduce their technology, the team demonstrated their ability to enhance comparisons of glycomics datasets by focusing on the hidden relationships between glycans in several contexts, including gastric cancer tissues. They used cancer as a useful example considering the importance of glycan changes to cancer and its utility for early-stage diagnosis.

 

access your free copy

 


Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing

This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Inside the report:

  • Advance discovery through miniaturised, high-throughput and animal-free systems
  • Integrate AI, robotics and analytics to speed decision-making
  • Streamline cell therapy and bioprocess QC for scale and compliance
  • And more!

This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today

 

“We applied GlyCompare to cancer tissues and showed that while one could not find cancer specific glycans using standard statistical methods, novel biomarkers emerge when processed using our method,” explained UC San Diego Professor of Bioengineering and Paediatrics Nathan Lewis, who is the corresponding author of the paper.

In another analysis, the team showed the method substantially boosts statistical power. The researchers showed that GlyCompare requires half as many samples to obtain equivalent power to detect biomarkers. In the paper, the researchers outline how the methods behind GlyCompare will be transformative for bringing glycomics to the clinic.

The researchers believe that this approach will enable the detection of more subtle changes in glycosylation in many applications, including early stage cancer. Moreover, GlyCompare could lead to new insights on the mechanisms behind the observed changes in glycans that are present.  

The team hope that GlyCompare will be widely used in the future and Lewis is part of the founding team of a new start-up that is licensing related intellectual property to commercialise this technology for high value applications, including cancer diagnostics. 

The study was published in Nature Communications.